INT6364
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Intracerebroventricular endothelin-1 (ET-1) produces Ca(2+)-mediated antinociception in mice. | |||||||||||||||
| |||||||||||||||
|
Intracerebroventricular endothelin-1 (ET-1) produces Ca(2+)-mediated antinociception in mice. | |||||||||||||||
| |||||||||||||||
|
In some diseases in which endothelin-1 (ET-1) production increases (e.g. prostate cancer), ET-1 is considered to be involved in the generation of pain. | |||||||||||||||
| |||||||||||||||
|
In some diseases in which endothelin-1 (ET-1) production increases (e.g. prostate cancer), ET-1 is considered to be involved in the generation of pain. | |||||||||||||||
| |||||||||||||||
|
The aim of the study was to examine whether endothelin-1 (ET-1) injected into dorsolateral periaqueductal gray (PAG) area of mice produces antinociception. | |||||||||||||||
| |||||||||||||||
|
These results suggest that selective endothelin ET(A) receptor antagonists might relieve pain in patients with various diseases in which endothelin-1 production is increased, e.g. prostate cancer. | |||||||||||||||
| |||||||||||||||
|
In some diseases in which endothelin-1 production increases, e.g. prostate cancer, endothelin-1 is considered to be involved in the generation of pain. | |||||||||||||||
| |||||||||||||||
|
In electrophysiological study, whole-cell patch-clamp recordings were performed to investigate the interaction of ET-1 and TRPV1 using human embryonic kidney 293 (HEK293) cells expressing endothelin type A receptor (ET(A)) and TRPV1. | |||||||||||||||
| |||||||||||||||
|
Intra-tumor expression of both ET-1 mRNA and ET-1 protein were significantly upregulated compared to normal tissue, and local administration of the ET-A receptor selective antagonist, BQ-123 (100 microM) significantly elevated withdrawal thresholds, indicating the induction of an antinociceptive effect. | |||||||||||||||
| |||||||||||||||
|
Intra-tumor expression of both ET-1 mRNA and ET-1 protein were significantly upregulated compared to normal tissue, and local administration of the ET-A receptor selective antagonist, BQ-123 (100 microM) significantly elevated withdrawal thresholds, indicating the induction of an antinociceptive effect. | |||||||||||||||
| |||||||||||||||
|
Indeed, when ET-1 in a dose of 0.003 nmol, which produced significant antinociception in non-diabetic mice, it had no antinociceptive effect in diabetic mice. | |||||||||||||||
| |||||||||||||||
|
Endothelin-1 (ET-1) exists in endothelial cells as well as a variety of other cell types. | |||||||||||||||
| |||||||||||||||
|
Endothelin-1 (ET-1) exists in endothelial cells as well as a variety of other cell types. | |||||||||||||||
| |||||||||||||||
|
The injection of endothelin-1 (ET-1) (2 pmol) into the dorsolateral periaqueductal gray area (PAG) of mice produces antinociceptive effect as underscored by increases in the latency time for the reaction to a hot plate. | |||||||||||||||
| |||||||||||||||
|
The injection of endothelin-1 (ET-1) (2 pmol) into the dorsolateral periaqueductal gray area (PAG) of mice produces antinociceptive effect as underscored by increases in the latency time for the reaction to a hot plate. | |||||||||||||||
| |||||||||||||||
|
Intracerebroventricular (i.c.v.) or intrathecal (i.t.) administration of morphine to mice antagonized the abdominal constriction induced by an i.p. injection of endothelin-1 (ET-1; 0.1 mg/kg). | |||||||||||||||
| |||||||||||||||
|
Intracerebroventricular (i.c.v.) or intrathecal (i.t.) administration of morphine to mice antagonized the abdominal constriction induced by an i.p. injection of endothelin-1 (ET-1; 0.1 mg/kg). | |||||||||||||||
| |||||||||||||||
|
The ET-1 level in the plasma was then determined by an Elisa technique (Human Endothelin Immunoassay, Catalog number QET00B, R&D Systems Inc. | |||||||||||||||
| |||||||||||||||
|
Measurement of ET-1 levels in blood | |||||||||||||||
| |||||||||||||||
|
Two groups of animals kept in room air (group C, n = 8) or were exposed to hyperoxia for 60 h (group Hox, n = 10) were not subjected to ET-1 receptor blockade, dual ETA/ETB-receptor blocker TEZ was administered continuously for 6 days via an intraperitoneal pump (10 mg/kg/day) to two other groups of mice, likewise kept in room air (group CT, n = 6) or exposed to hyperoxia for 60 h (group HoxT, n = 7). | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.